<?xml version='1.0' encoding='utf-8'?>
<document id="31047942"><sentence text="Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions."><entity charOffset="19-29" id="DDI-PubMed.31047942.s1.e0" text="Everolimus" /><entity charOffset="34-43" id="DDI-PubMed.31047942.s1.e1" text="Sirolimus" /><pair ddi="false" e1="DDI-PubMed.31047942.s1.e0" e2="DDI-PubMed.31047942.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31047942.s1.e0" e2="DDI-PubMed.31047942.s1.e1" /></sentence><sentence text="Organic anion transporting polypeptides (OATP)1B1 and OATP1B3 mediate hepatic uptake of many drugs including lipid-lowering statins" /><sentence text=" Current studies determined the OATP1B1/1B3-mediated drug-drug interaction (DDI) potential of mammalian target of rapamycin (mTOR) inhibitors, everolimus and sirolimus, using R-value and physiologically based pharmacokinetic models"><entity charOffset="114-123" id="DDI-PubMed.31047942.s3.e0" text="rapamycin" /><entity charOffset="143-153" id="DDI-PubMed.31047942.s3.e1" text="everolimus" /><entity charOffset="158-167" id="DDI-PubMed.31047942.s3.e2" text="sirolimus" /><pair ddi="false" e1="DDI-PubMed.31047942.s3.e0" e2="DDI-PubMed.31047942.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31047942.s3.e0" e2="DDI-PubMed.31047942.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31047942.s3.e0" e2="DDI-PubMed.31047942.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31047942.s3.e1" e2="DDI-PubMed.31047942.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31047942.s3.e1" e2="DDI-PubMed.31047942.s3.e2" /></sentence><sentence text=" Preincubation with everolimus and sirolimus significantly decreased OATP1B1/1B3-mediated transport even after washing and decreased inhibition constant values up to 8"><entity charOffset="20-30" id="DDI-PubMed.31047942.s4.e0" text="everolimus" /><entity charOffset="35-44" id="DDI-PubMed.31047942.s4.e1" text="sirolimus" /><pair ddi="false" e1="DDI-PubMed.31047942.s4.e0" e2="DDI-PubMed.31047942.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31047942.s4.e0" e2="DDI-PubMed.31047942.s4.e1" /></sentence><sentence text="3- and 2" /><sentence text="9-fold for OATP1B1 and both 2" /><sentence text="7-fold for OATP1B3, respectively" /><sentence text=" R-values of everolimus, but not sirolimus, were greater than the FDA-recommended cutoff value of 1"><entity charOffset="13-23" id="DDI-PubMed.31047942.s8.e0" text="everolimus" /><entity charOffset="33-42" id="DDI-PubMed.31047942.s8.e1" text="sirolimus" /><pair ddi="false" e1="DDI-PubMed.31047942.s8.e0" e2="DDI-PubMed.31047942.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31047942.s8.e0" e2="DDI-PubMed.31047942.s8.e1" /></sentence><sentence text="1" /><sentence text=" Physiologically based pharmacokinetic models predict that everolimus and sirolimus have low OATP1B1/1B3-mediated DDI potential against pravastatin"><entity charOffset="59-69" id="DDI-PubMed.31047942.s10.e0" text="everolimus" /><entity charOffset="74-83" id="DDI-PubMed.31047942.s10.e1" text="sirolimus" /><entity charOffset="136-147" id="DDI-PubMed.31047942.s10.e2" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.31047942.s10.e0" e2="DDI-PubMed.31047942.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31047942.s10.e0" e2="DDI-PubMed.31047942.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31047942.s10.e0" e2="DDI-PubMed.31047942.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31047942.s10.e1" e2="DDI-PubMed.31047942.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31047942.s10.e1" e2="DDI-PubMed.31047942.s10.e2" /></sentence><sentence text=" OATP1B1/1B3-mediated transport was not affected by preincubation with INK-128 (10 μM, 1 h), which does however abolish mTOR kinase activity" /><sentence text=" The preincubation effects of everolimus and sirolimus on OATP1B1/1B3-mediated transport were similar in cells before preincubation with vehicle control or INK-128, suggesting that inhibition of mTOR activity is not a prerequisite for the preincubation effects observed for everolimus and sirolimus"><entity charOffset="30-40" id="DDI-PubMed.31047942.s12.e0" text="everolimus" /><entity charOffset="45-54" id="DDI-PubMed.31047942.s12.e1" text="sirolimus" /><entity charOffset="274-284" id="DDI-PubMed.31047942.s12.e2" text="everolimus" /><entity charOffset="289-298" id="DDI-PubMed.31047942.s12.e3" text="sirolimus" /><pair ddi="false" e1="DDI-PubMed.31047942.s12.e0" e2="DDI-PubMed.31047942.s12.e0" /><pair ddi="false" e1="DDI-PubMed.31047942.s12.e0" e2="DDI-PubMed.31047942.s12.e1" /><pair ddi="false" e1="DDI-PubMed.31047942.s12.e0" e2="DDI-PubMed.31047942.s12.e2" /><pair ddi="false" e1="DDI-PubMed.31047942.s12.e0" e2="DDI-PubMed.31047942.s12.e3" /><pair ddi="false" e1="DDI-PubMed.31047942.s12.e1" e2="DDI-PubMed.31047942.s12.e1" /><pair ddi="false" e1="DDI-PubMed.31047942.s12.e1" e2="DDI-PubMed.31047942.s12.e2" /><pair ddi="false" e1="DDI-PubMed.31047942.s12.e1" e2="DDI-PubMed.31047942.s12.e3" /><pair ddi="false" e1="DDI-PubMed.31047942.s12.e2" e2="DDI-PubMed.31047942.s12.e2" /><pair ddi="false" e1="DDI-PubMed.31047942.s12.e2" e2="DDI-PubMed.31047942.s12.e3" /></sentence><sentence text=" Nine potential phosphorylation sites of OATP1B1 were identified by phosphoproteomics; none of these are the predicted mTOR phosphorylation sites" /><sentence text=" We report the everolimus/sirolimus-preincubation-induced inhibitory effects on OATP1B1/1B3 and relatively low OATP1B1/1B3-mediated DDI potential of everolimus and sirolimus"><entity charOffset="15-25" id="DDI-PubMed.31047942.s14.e0" text="everolimus" /><entity charOffset="26-35" id="DDI-PubMed.31047942.s14.e1" text="sirolimus" /><entity charOffset="149-159" id="DDI-PubMed.31047942.s14.e2" text="everolimus" /><entity charOffset="164-173" id="DDI-PubMed.31047942.s14.e3" text="sirolimus" /><pair ddi="false" e1="DDI-PubMed.31047942.s14.e0" e2="DDI-PubMed.31047942.s14.e0" /><pair ddi="false" e1="DDI-PubMed.31047942.s14.e0" e2="DDI-PubMed.31047942.s14.e1" /><pair ddi="false" e1="DDI-PubMed.31047942.s14.e0" e2="DDI-PubMed.31047942.s14.e2" /><pair ddi="false" e1="DDI-PubMed.31047942.s14.e0" e2="DDI-PubMed.31047942.s14.e3" /><pair ddi="false" e1="DDI-PubMed.31047942.s14.e1" e2="DDI-PubMed.31047942.s14.e1" /><pair ddi="false" e1="DDI-PubMed.31047942.s14.e1" e2="DDI-PubMed.31047942.s14.e2" /><pair ddi="false" e1="DDI-PubMed.31047942.s14.e1" e2="DDI-PubMed.31047942.s14.e3" /><pair ddi="false" e1="DDI-PubMed.31047942.s14.e2" e2="DDI-PubMed.31047942.s14.e2" /><pair ddi="false" e1="DDI-PubMed.31047942.s14.e2" e2="DDI-PubMed.31047942.s14.e3" /></sentence><sentence text="" /></document>